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Summary
Cytokines of the interleukin-1 (IL-1) family, such as
IL-1a/b and IL-18, have important functions in host
defense, immune regulation, and inflammation. Insight
into their biological functions has led to novel thera-
peutic approaches to treat human inflammatory dis-
eases. Within the IL-1 family, IL-1a/b, IL-1Ra, and
IL-18 have been matched to their respective receptor
complexes and have been shown to have distinct bio-
logical functions. The most prominent orphan IL-1 re-
ceptor is ST2. This receptor has been described as
a negative regulator of Toll-like receptor-IL-1 receptor
signaling, but it also functions as an important effector
molecule of T helper type 2 responses. We report
a member of the IL-1 family, IL-33, which mediates its
biological effects via IL-1 receptor ST2, activates NF-
kB and MAP kinases, and drives production of TH2-as-
sociated cytokines from in vitro polarized TH2 cells. In
vivo, IL-33 induces the expression of IL-4, IL-5, and IL-
13 and leads to severe pathological changes in muco-
sal organs.
Introduction
IL-1 family members are known to alter the host re-
sponse to an inflammatory, infectious, or immunological
challenge (Dinarello, 1994, 2000). The four best known
members of this family are IL-1a/b, IL-1Ra, and IL-18.
IL-1a/b and IL-18 are highly inflammatory cytokines,
and dysregulation of their expression can lead to severe
pathobiological effects. Accordingly, the expression of
these cytokines is highly regulated via both soluble re-
ceptors (e.g., type 2 IL-1 receptor) and natural antago-
nist proteins (e.g., IL-1Ra and IL-18 binding protein) as
well as alternatively spliced forms of both ligands and
receptors (Dinarello, 1997; Dunne and O’Neill, 2003).
With the exception of IL-18, all IL-1 genes are clustered
on human chromosome 2, including several new IL-1
*Correspondence: jfbazan@gene.com (J.F.B.); rob.kastelein@dnax.
org (R.A.K.)
3Present address: Department of Protein Engineering, Department
of Molecular Biology, Department of Immunology, Genentech,
Inc., Mail Stop 37, 1 DNA Way, S. San Francisco, California 94080.family members called IL-1F5-F10 for which no clear
function has yet emerged (Sims et al., 2001).
IL-1 cytokines exert their function through a family of
receptors that belong to the Toll-like receptor-IL-1 re-
ceptor (TLR-IL-1R) superfamily, which is defined by
the presence of an intracellular Toll-IL-1R (TIR) module.
This superfamily can be divided into two main groups,
the Toll-like receptors and receptors of the IL-1 family.
The IL-1 receptor family currently has 10 members, and
IL-1 ligands typically bind to a cellular receptor com-
plex that consists of two members of this family. The
receptor complex for IL-1a/b consists of IL-1R1 and
IL-1RAcP, with IL1Ra acting as a natural antagonist
of IL-1a/b by trapping IL-1R1 molecules. IL-18 medi-
ates its function via IL-18Ra and IL-18Rb, with IL-18
binding protein (IL-18bp) acting as a negative regulator
(Dunne and O’Neill, 2003). The only other IL-1 receptor
that has been matched to ligands is IL-1Rrp2 (Debets
et al., 2001; Towne et al., 2004). The hallmark of IL-1 re-
ceptors signaling is the activation of the transcription
factor NF-kB and the mitogen-activated protein (MAP)
kinases p38, JNK, and ERK1/2 (Dunne and O’Neill,
2003).
Thus far, the IL-1 receptor family members ST2,
SIGIRR, IL-1RAPL, and IL-1RAPL2 have eluded ligand
identification. Of these, the best-known orphan IL-1 re-
ceptor is ST2 (also called DER4, Fit-1, or T1). Originally
identified 16 years ago as a serum-inducible secreted
protein in murine fibroblast (Bergers et al., 1994;
Klemenz et al., 1989; Tominaga, 1989; Tominaga et al.,
1991, 1992), ST2 in its transmembrane form is expressed
primarily on mast cells and on TH2 cells and is linked to
important TH2 effector functions (Coyle et al., 1999;
Lohning et al., 1998, 1999; Moritz et al., 1998; Townsend
et al., 2000; Xu et al., 1998). Treatment of mice either with
an antagonistic antibody against ST2 or with an IgG-ST2
fusion protein leads to an enhancement of T helper type
1 (TH1) responses and has an inhibitory effect on TH2-
associated allergic airway inflammation (Lohning et al.,
1998; Xu et al., 1998). Although two putative ligands for
ST2 have been reported, neither of these proteins trigger
activation of NF-kB, nor are they related to IL-1 family
cytokines (Gayle et al., 1996; Kumar et al., 1995). Re-
cently, ST2 has been described as a negative regulator
of TLR-IL-1R receptor signaling (Brint et al., 2004), in
line with an earlier report that ST2 was unable to activate
the classical IL-1-activated transcription factor NF-kB
(Brint et al., 2002; Thomassen et al., 1999).
In this study, we present a member of the IL-1 family
that binds to IL-1 receptor ST2. Like IL-1b and IL-18,
IL-33 (also labeled IL-1F11, following IL-1 family nomen-
clature [Sims et al., 2001]) is produced in a precursor
form and can be cleaved by caspase-1. The binding of
IL-33 to cells that express ST2 results in the activation
of NF-kB and MAP kinases. Administration of purified
IL-33 either in vitro or in vivo leads to the production of
TH2-associated cytokines. Furthermore, in mice, IL-33
induces eosinophilia, splenomegaly, and increased lev-
els of serum Ig—leading to profound histopathological
changes in the lungs and gastrointestinal (GI) tract.
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480Figure 1. Alignment of Human and Mouse IL-33 Protein Sequences
(A) Sequence alignment of human and mouse IL-33 proteins. Gray arrows indicate the 12 predicted b strands of the IL-1 fold. The arrowhead
indicates the start of the recombinant proteins.
(B) Phylogenetic tree for representative members of the human IL-1 family. The dendrogram was derived by the neighbor-joining method within
ClustalX and is rooted by the FGF relatives of IL-1.
(C) In vitro translated 35S-labeled full-length IL-33 is cleaved by caspase-1. Pro-hIL-33 and mature IL-33 are indicated.Results
Identification of IL-33 as an IL-1 Family Member
We searched sequence databases with a computation-
ally derived profile of members of the IL-1 cytokine fam-
ily (see Experimental Procedures). This effort led to the
identification of an IL-1 family member that we have
named IL-33 (IL-1F11). The human gene is located on
chromosome 9p24.1, while its mouse counterpart can
be found on the syntenic chromosome 19qC1 region.
The IL-33 cDNA sequences encode 270 and 266 amino
acid polypeptides for human and mouse, respectively
(Figure 1A), corresponding to full-length proteins with
calculated masses of 30 and 29.9 kDa. IL-33 is ex-
pressed as a prodomain containing polypeptide. Incu-
bation of in vitro translated IL-33 with caspase-1 led to
the production of mature IL-33 with a mass of 18 kDa
as determined by SDS-PAGE (Figure 1C). Human and
mouse IL-33 are 55% identical at the amino acid level.
The IL-1 family member most closely related to IL-33 is
IL-18 (Figure 1B).
Expression Profile of IL-33
Analysis of a panel of human and mouse cDNA libraries
by real-time quantitative PCR showed that IL-33 mRNA
is broadly expressed in many tissues but is more re-
stricted at the level of cell types (Figures 2A and 2B).
High levels of mouse IL-33 mRNA can be found in the
stomach, lung, spinal cord, brain, and skin. Lower levels
of mouse IL-33 mRNA were observed in lymph tissue,spleen, pancreas, kidney, and heart. Human smooth
muscle cells (SMC) of various tissues as well as epithe-
lial cells forming the bronchus or small airways showed
a constitutive expression of IL-33 mRNA, whereas in pri-
mary lung or dermal fibroblasts and keratinocytes, IL-33
gene expression was induced afteractivation with TNF-a
and IL-1b. Activated dendritic cells and macrophages
are the only hematopotietic cells that show low quanti-
ties of human IL-33 mRNA. In contrast, mouse IL-33
mRNA was found in resting dendritic cells and activated
macrophages.
IL-33 Forms a Complex with the Orphan IL-1
Receptor ST2
For both IL-1a/b and IL-18, one of the receptor chains
functions as a primary binding component, while the
second chain contributes little to binding but is neces-
sary for signal transduction (Dunne and O’Neill, 2003).
We tested ST2, the orphan IL-1 receptor most closely re-
lated to IL-1R1 and IL-18Ra, as the primary binding re-
ceptor for IL-33. E. coli-expressed and purified mature
human IL-33 (residues 112–270) was biotinylated and
precipitated via avidinbeads in the presence of ST2-Fc
fusion protein. The precipitates were monitored for the
presence of ST2-Fc by Western blot by use of antibodies
directed against human ST2 (Figure 3A). ST2 was immu-
noprecipitated in the presence of IL-33 (Figure 3A, lane
3). Some background binding of the ST2-Fc occurred
in the absence of IL-33 (Figure 3A, lane 2), but the corre-
sponding ST2-Fc protein band was significantly more
IL-33: An IL-1 Cytokine
481Figure 2. Distribution of IL-33 in Tissues and Cell Types
Real-time quantitative PCR was performed for IL-33 on various mouse (A) and human (B) cDNA libraries. Human cDNA libraries index (top to
bottom): mesangial cells resting; dermal fibroblasts (DF) activated and resting; lung fibroblast (LF) activated and resting; bronchial smooth mus-
cle cells (SMC) activated and rested; pulmonary artery SMC resting; coronary artery SMC resting; keratinocytes activated and resting; various
resting epithelial cells (EC) and activated small airway EC; monocyte-derivate dendritic cells (DC) activated with LPS and resting; monocytes
(MC) activated with LPS and resting; hematopoietic precursor TF1; natural killer cells activated and resting; B cell lines activated and resting;
splenocytes activated and resting; T cell subsets activated and resting; peripheral blood mononuclear cells activated and resting. Mouse
cDNA libraries index (top to bottom): various tissues; epithelial cells activated and resting; peritoneal macrophages; macrophages from bone
marrow activated with LPS and resting; dendritic cells from bone marrow activated and resting; B cells; Mel14+ T cell subset; L-fibroblast.prominent in the presence of IL-33 (Figure 3A, lane 3).
Next we investigated pull-down of IL-33 via ST2. ST2 fu-
sion protein was precipitated via Protein-G-Sepharose
in the presence of biotinlyated IL-33. ST2 was capable
of binding biotinylated IL-33 (Figure 3B, lane 2). No bind-
ing occurred when only Protein-G-Sepharose and bioti-
nylated IL-33 were present (Figure 3B).
IL-33 Signals via ST2
The ability of ST2 to bind IL-33 suggested that this re-
ceptor is part of a functional IL-33 receptor complex.
To test this hypothesis, we investigated whether IL-33
could initiate signaling via this receptor by using an
NF-kB-dependent reporter assay. We transiently trans-
fected HEK293FT cells either with a mock mammalian
expression vector or with an expression vector encod-
ing ST2 in conjunction with an NF-kB-driven GFP
expression construct. Real-time PCR analysis of un-
transfected HEK293 cells showed no endogenous ex-
pression of ST2 (data not shown). After stimulation of
the transiently transfected cells with mouse IL-33 for
16 hr, cells were analyzed for GFP expression by FACS
analysis (Figure 3C). A small population of cells, trans-
fected only with the GFP-reporter gene construct, ex-
pressed GFP, but this population did not increase after
stimulation of these cells with IL-33. In contrast, expres-
sion of ST2 led to the induction of GFP upon stimulation
with IL-33 (Figure 3C). To examine what proximal signal-
ing components are utilized by IL-33-ST2-mediated sig-
naling, cell extracts of 293 cells transfected with humanST2 untreated or stimulated with 10 ng/ml IL-33 were
immunoprecipitated with anti-ST2 antibody, followed
by Western analysis with anti-MyD88, IRAK4, IRAK,
TRAF6, and ST2 antibodies. As shown in Figure 3D,
MyD88, IRAK, IRAK4, and TRAF6 are all recruited to
ST2 upon IL-33 stimulation. We also monitored these
extracts for activation of downstream signaling path-
ways. As shown in Figure 3E (right panel), IL-33 stimula-
tion of ST2-transfected 293 cells leads to phosphoryla-
tion of IkBa as well as the kinases Erk1/2, p38, and JNK
with a peak of phosphorylation occurring at 15 min.
This pattern of IL-33/ST2-induced phosphorylation is
similar to the signaling events induced in 293 cells trans-
fected with IL-1R1 and stimulated with IL-1b (Figure 3E,
left panel).
IL-33 Induces NF-kB Phosphorylation and Activates
MAP Kinases in Mast Cells
We next investigated whether IL-33 is able to induce sig-
naling in cells that naturally express ST2. We tested
mouse mast cells (WTMC) for the cell-surface expres-
sion of ST2. Expression of ST2 was readily detected
by FACS analysis using a ST2 antibody (Figure 4A, left
panel). Binding of the ST2 antibody could be abrogated
with IL-33, and we could demonstrate binding of biotiny-
lated IL-33 to these cells (Figure 4A, right panel). To an-
alyze the signaling pathways induced by IL-33, we stim-
ulated this mast cell line with IL-33 and monitored the
phosphorylation of NF-kB and various MAP kinases
(Figures 4B and 4C). Phosphorylation of NF-kB was
Immunity
482Figure 3. IL-33 Receptor Matching and ST2-Receptor Complex
(A) Pull-down of recombinant extracelluar ST2 Fc-fusion protein via biotinylated IL-33. Biotinylated IL-33 was precipitated via Avidinbeads in the
presence or absence of ST2-Fc as indicated. The precipitated proteins were separated by SDS-PAGE, electroblotted, and visualized by Western
blot/ECL reaction with anti-ST2.
(B) Pull-down of biotinylated IL-33 with ST2-Fc fusion protein. ST2-Fc fusion protein was incubated with IL-33-biotin and precipitated with Pro-
tein G-Sepharose. The precipitates were separated by SDS-PAGE, electroblotted, and monitored for the presence of biotinylated IL-33.
(C) HEK293FT cells (43 106) were transfected with 1.3 mg of pNF-kB-GFP reporter gene plasmid and with either 1.3 mg of pME18S-mST2 plasmid
or with empty control vector. 24 hr after transfection, cells were split. 24 hr later, cells were left untreated or were stimulated for 16 hr with IL-33
(50 ng/ml). GFP expression was monitored by FACS analysis.
(D) Cell extracts prepared from 293/ST2 cells untreated or stimulated with 10 ng/ml IL-33 were immunoprecipitated with anti-ST2 antibody, fol-
lowed by Western analysis with anti-MyD88, IRAK4, IRAK, TRAF6, or ST2 antibodies.
(E) Cell extracts prepared from 293 cells transfected with IL-1RI (left) or ST2 (right), untreated or stimulated with 10 ng/ml IL-1b or 10 ng/ml IL-33,
respectively, were blotted with anti-phospho-Erk1/2, anti-phospho-p38, anti-phospho-IkBa, or anti-phospho-JNK antibodies. Loading of equal
amounts of proteins was determined by restaining of the blots with anti-JNK antibody.observed in the total cell lysate after IL-33 stimulation
with a peak of phosphorylation occurring at 15 min
and decreased levels at 30 min. NF-kB phosphorylationcould be significantly blocked by preincubation of the
cells with a neutralizing anti-ST2 antibody prior to stim-
ulation with IL-33 (Figure 4B). A control antibody was not
IL-33: An IL-1 Cytokine
483Figure 4. IL-33-Induced NF-kB Phosphorylation and MAPK Activation and TH2 Cytokine Production
(A) Left: WTMC cells were incubated with either 1.5 mg of isotype control antibody (purple), 1.5 mg anti-ST2 antibody (green), 1.5 mg anti-ST2 an-
tibody and 0.8 mg of rhIL-33 (magenta), 1.5 mg anti-ST2 antibody and 2 mg of hIL-33 (blue), or 1.5 mg anti-ST2 antibody and 4 mg of hIL-33 (orange).
Cells were washed and incubated with an anti-rat IgG-PE antibody. Cells were analyzed by FACS. Right: WTMC cells were either untreated (pur-
ple) or incubated with 0.4 mg of biotinylated hIL-33 (green) or incubated with a combination of 0.4 mg of biotinylated and 4 mg of hIL-33 (magenta).
Cells were washed, incubated with streptavidin-PE, and analyzed by FACS.
(B and C) WTMC cells were preincubated in the presence or absence of either anti-mST2 mAb or an isotype control mAb at a concentration of
1 mg/ml. Cells were stimulated with 1.5 ng/ml IL-33 for various times or were left unstimulated as indicated. Cell lysates were separated by SDS-
PAGE and electroblotted. The presence of phosphorylated proteins was monitored by Western blot/ECl reaction using phospho-specific anti-
bodies. Loading of equal amounts of proteins was determined by restaining of the blots with antibodies directed against NF-kB, Erk1/2, or p38.
(D) TH1- and TH2-polarized cells were restimulated with anti-CD3/28 in the presence or absence of IL-33 (20 ng/ml). After 48 hr, the supernatant
were monitored for IFNg, IL-4, IL-5, and IL-13.capable of reducing phosphorylation (Figure 4B), and
neither was the anti-ST2 antibody on its own able to in-
duce activation of NF-kB. In addition to NF-kB, IL-33
also induced activation of Erk1/2 and p38 (Figure 4C).
Phosphorylation of these kinases could also be inhibited
by anti-ST2 antibody. Activation of JNK kinases was
also observed (data not shown).
IL-33 Stimulates Cytokine Expression of In Vitro
TH2-Polarized Naive T Cells
ST2 is required for development of effective TH2 re-
sponses (Trajkovic et al., 2004). To test whether IL-33
could stimulate TH2 cells to produce TH2 cytokines, we
isolated naive T cells from C57BL/6 spleens and polar-
ized these cells into TH1 with IL-12 or TH2 cells with IL-4
(Boonstra et al., 2001). After three rounds of polarization,
cells were restimulated with anti-CD3 and anti-CD28
with or without IL-33 (20 ng/ml), and supernatants were
tested for the expression of IFNg, IL-4, IL-5, and IL-13.TH2 cells but not TH1 cells responded to IL-33 stimulation
with increased production of IL-5 and IL-13 (Figure 4D).
The production of IL-4 was already high and not further
increased with the addition of IL-33. As expected, TH1
cells produced high levels of IFNg. Interestingly, this
level was reduced when the cells were incubated with
IL-33.
IL-33 Protein Treatment of Mice Induces
Splenomegaly, Eosinophilia, and Serum IgE
To understand the in vivo biological function of IL-33, we
injected wt mice intraperitoneally (i.p.) with IL-33 protein
and monitored the mice for changes in hematopoietic
parameters. Mice treated daily with 0.4 or 4 mg of IL-33
for 7 days developed splenomegaly with significantly
higher numbers of eosinophils, mononuclear cells, and
plasma cells, but not neutrophils (Figures 5A and 5B).
The increased number of splenic eosinophils and mono-
nuclear cells correlated with an increase in blood
Immunity
484Figure 5. In Vivo Treatment with IL-33 Leads to Splenomegaly, Eosinophilia, and Increased Levels of Serum IgA and IgE
(A and B) C57BL/6 mice (n = 4–5) were injected i.p. daily with either 0.4 mg or 4 mg IL-33 or with PBS for 7 days. Spleens were harvested, weighed,
and made into single-cell suspension to determine total cellularity. Relative populations were determined microscopically with Haema3-stained
cytospins (*p < 0.05; **p < 0.01).
(C) C57BL/6 mice (n = 5) were treated for 7 days with either 0.4 mg or 4 mg IL-33 protein or with phosphate-buffered saline. At day 8, blood was
taken for total white blood cell and differential blood cell count (*p < 0.05; **p < 0.01).
(D) Serum Ig isotype levels were determined by sandwich ELISA. Results shown are representative of two independent experiments (*p < 0.05).eosinophils and lymphocytes (Figure 5C). No significant
changes were observed in the numbers of blood neutro-
phils and monocytes. Evaluation of circulating Ig levels
showed that IL-33-treated mice had significantly higher
serum levels of IgE and IgA (Figure 5D).
IL-33 Induces Gene Expression
of TH2-Associated Cytokines
The increased eosinophil levels induced by IL-33 could
be associated with an increase in IL-5 expression, while
IgE and IgA synthesis could be associated with IL-4 and
IL-13 expression (Bost et al., 1996; Chomarat and Ban-
chereau, 1998; Roboz and Rafii, 1999). Therefore, we
tested whether IL-33 could induce expression of TH2-
associated cytokines in vivo. Total tissue mRNA was
isolated from mice treated with either 0.4 or 4 mg IL-33
per day and tested for the presence of IL-4, IL-5, and
IL-13 mRNA by quantitative PCR analysis. IL-33 treat-
ment strongly induced gene expression of IL-13 in all tis-
sues tested, including thymus, spleen, liver, small intes-
tine, and lung (Figure 6A and data not shown). mRNA
expression of both IL-4 and IL-5 was higher in thymus,
spleen, liver, and lung of IL-33-treated mice. There was
no change in the gene expression of IL-1a, IL-2, TNFa,
IL-10, IL-12, or IFNg (data not shown). The serum of
IL-33-treated mice showed highly increased levels of
IL-5 and IL-13 (Figure 6B). Serum levels of IL-2, IL-4,
IL-6, IL-10, IL-12, TNFa, IFNg, or MCP-1 were either
not detectable or did not change in comparison to
PBS-treated animals (data not shown).IL-33 Induces Pathological Changes in the Lung
and the Digestive Tract
We also observed gross anatomical changes in IL-33-
treated mice, including enlargement of spleen and stom-
ach and mucus- and bile-filled duodenum. Microscopic
examination showed striking histological changes in
mucosal tissues, including the lung, esophagus, and
small intestine. In the lung, vascular changes were ob-
served in medium and small muscular arteries com-
pared to untreated lung (Figures 7A–7D). Changes in-
cluded minimal to moderate medial hypertrophy and
the presence of myeloid cells within the vascular lumen
and infiltrates of eosinophils and/or mononuclear cells
beneath the endothelium, within the vessel wall, and ad-
jacent to the vessels. Changes in the airways were pri-
marily restricted to the bronchi and larger bronchioles
(Figures 7E and 7F). The epithelial lining of the airways
was hypertrophied and appeared to contain large
amounts of mucus. Periodic acid-Schiff (PAS) and alcian
blue staining highlighted the presence of mucus within
the epithelial lining. In some mice, mucus filled the entire
airway lumina. In the digestive tract, epithelial hyperpla-
sia was evident in the esophagus (data not shown). In-
flammatory infiltrates of eosinophils, neutrophils, and
mononuclear cells were seen in the epithelium and lam-
ina propria of the esophagus. Epithelial cells often con-
tained prominent esoninophilic cytoplasmic inclusions
(data not shown). In the small and large intestines, the
goblet cells were hypertrophied and hyperplastic (Fig-
ures 7G and 7H), and lumen of the intestines sometimes
IL-33: An IL-1 Cytokine
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scopic investigation of the enlarged spleen showed ex-
tramedullary hematopoesis attended by the distortion of
red and white pulp (Figures 7I and 7J).
Discussion
We describe an IL-1 family member called IL-33 that is
most closely related in structure to IL-18 and IL-1b.
Like these two ‘‘classical’’ IL-1 family members, IL-33
is expressed as a prodomain-containing protein, which
is processed for optimal biological activity. IL-1b and
IL-18 have profound biological activities as regulators
of immune and inflammatory responses (Dinarello,
1997, 2000), and indeed, we find that IL-33 also displays
strong immunomodulatory functions. However, whereas
IL-1b and IL-18 promote proinflammatory and TH1-
associated responses (Dinarello, 1994; Robinson et al.,
1997), IL-33 leads to the production of TH2-associated
cytokines and increased serum immunoglobulin levels.
The existence of an IL-1 family member with the biolog-
ical profile as described here for IL-33 has long been an-
ticipated, based on the presence of the IL-1R family
member ST2 as a selective marker of TH2 cells and its
role in regulation of effective TH2 responses (Coyle
et al., 1999; Lohning et al., 1998; Xu et al., 1998). How-
ever, how ST2 contributes to TH2 responses has re-
mained unclear. Two previously identified putative ST2
ligands do not affect TH2 functions and are not related
to IL-1 cytokines, and their physiological relevance re-
mains uncertain (Gayle et al., 1996; Kumar et al., 1995).
The close structural relationship between IL-33, IL-18,
and IL-1b and the equally close relationship between
receptor family members IL-1R1, IL-18Ra, and ST2
prompted us to rapidly identify ST2 as a subunit of the
IL-33 receptor. The TH2-associated biological activities
that we report are in agreement with IL-33 being the
true ligand for ST2. We have started a search for the sec-
ond chain of the IL-33 receptor complex. Possible candi-
dates are the orphan IL-1 receptor SIGIRR or IL-1RAcP.
Both receptors are widely expressed and present on
cells we have used in the experiments described here
(Towne et al., 2004). Experiments are currently underway
in our laboratories.
IL-1 and FGF family members display 12 core
b strands that make up the characteristic b-trefoil fold
(Priestle et al., 1988). The b strands identified by struc-
tural alignment of mature IL-33 with members of the
IL-1 family are shown in Figure 1A. The phylogenetic
tree of the IL-1 family shows the outlier relationship of
(mature) IL-33 to the rest, though IL-18 appears as the
Figure 6. IL-33 Leads to Induction of IL-4, IL-5, and IL-13 Genes and
Protein Expression
(A) C57BL/6 mice (pool of 3 mice) were treated daily with either 0.4
mg or 4 mg of IL-33 protein or PBS for 7 days, and then organs
were harvested. Total RNA was isolated from individual tissues,
and IL-4, IL-5, and IL-13 mRNAs were quantified by real-time PCR
as described in Experimental Procedures.
(B) C57BL/6 mice (n = 3–5 per group) were treated daily with either
0.4 mg or 4 mg of IL-33 protein or PBS for 7 days and blood was col-
lected. IL-5 and IL-13 serum concentrations were measured either
by cytometric bead array (IL-5) or by sandwich ELISA (IL-13). The re-
sults shown are typical of three independent experiments (*p < 0.05;
**p < 0.01).
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486Figure 7. Microscopic Changes in Mice Re-
ceiving 0.4 mg of IL-33 Protein for 7 Days
(A–D) Pulmonary changes in mice receiving
IL-33 protein (hematoxylin and eosin [H&E]).
(A) Section of normal lung from PBS-treated
mice (PAS-AB).
(B) Vascular changes are localized to medium
and small muscular arteries. The larger mus-
cular artery had no changes, while the smaller
branch (arrow) has mild medial hypertrophy
and infiltrates of inflammatory cells (803).
(C) Higher magnification of a control muscu-
lar artery.
(D) Mononuclear and a few myeloid cells al-
most occluded the arterial lumen as well as
focal periateriolar mononuclear and myeloid
cell infiltrates.
(E and F) Epithelial changes in the lungs.
Proximal airway (*) (periodic acid-Schiff and
alcian blue [PAS-AB] stain,340 [inset3120]).
(E) Lung from mouse that received PBS. Inset
higher magnification of bronchiole.
(F) Lung from mouse that received IL-33 pro-
tein. Intense PAS-AB-positive staining in the
proximal airway epithelium. Inset: higher
magnification of bronchiole.
(G and H) Jejunal changes (PAS-AB, 380).
(G) Jejunum from mouse receiving PBS.
(H) Jejunum from mouse receiving IL-33 pro-
tein. Hypertrophy and hyperplasia of goblet
cells.
(I and J) Spleen changes (H&E, 3120).
(I) Spleen from mouse receiving PBS.
(J) Spleen from mouse receiving IL-33 pro-
tein. Loss of the organizational structure of
white and red pulp; extramedullary hemato-
poiesis.closest homolog (Figure 1B). Of the now 11 members of
the IL-1 family, only IL-33 and IL-18 are not linked to the
IL-1 gene cluster on human chromosome 2. Like IL-18
and IL-1b, IL-33 is produced with a long prodomain
that can be cleaved, at least in vitro, by caspase-1. We
do not yet know if caspase-1 is also responsible for pro-
cessing of pro-IL-33 in vivo. Efforts to identify a cellular
source to isolate and characterize natural IL-33 protein
are in progress.
IL-33 shows a different expression pattern in compar-
ison to IL-1b and IL-18. Although hematopoietic cells
seem to be the main source of IL-1b and IL-18, we can
detect only low levels of human IL-33 mRNA in this cell
type. Despite its relative scarcity in hematopoietic cells,
IL-33 mRNA is broadly expressed in various organs. Ex-
pression within these organs is restricted to a few celltypes, such as epithelial cells from the bronchus or the
small airways, fibroblasts, and smooth muscle cells.
Some expression of mouse IL-33 mRNA was seen in
dendritic cells, activated macrophages, and in TH2 cells,
but in general levels are low.
IL-33 plays an important role in TH2-associated immu-
nology. We show that in vitro polarized TH2 cells upon
restimulation respond to IL-33 by significantly increas-
ing secretion of IL-5 and IL-13. In these highly polarized
cells, we did not observe a further increase in the already
high production of IL-4, although in vivo administration
of IL-33 clearly induced IL-4 mRNA in multiple tissues.
These findings point to an important role for IL-33, and
its receptor ST2, in the induction of TH2 effector func-
tions. While these results confirm an effector function
for ST2, there has not been agreement on the question
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et al., 1999; Townsend et al., 2000). In initial experiments
to address this issue, we do not see, at least under
in vitro culture conditions, a role for IL-33 in driving
TH2 cell development (J.S., unpublished results). Inter-
estingly, IL-18 plays a similar role in TH1 cells: while
IL-18 has important TH1 effector functions and strongly
synergizes with IL-12 to produce IFNg, it does not play
a role in the development of TH1 cells (Robinson et al.,
1997). When administered in vivo, IL-33 has no effects
on mRNA levels of IL-1b, IL-2, IL-10, IL-12p40, TNFa,
INFg, and G-CSF (data not shown), but we detect signif-
icant increases in gene expression of prominent TH2-
associated cytokines IL-4, IL-5, and IL-13. In addition,
we can detect IL-5 and IL-13 in the serum of mice as
early as 3 days after administration of IL-33. Further-
more, treatment of mice with IL-33 leads to blood eosin-
ophilia, splenomegaly, and increased IgE and IgA iso-
types. The increased serum IgE is likely related to the
increased production of IL-4 (Chomarat and Bancher-
eau, 1998; Corry, 1999; Pene et al., 1988). Exposure to
IL-33 causes striking histological changes in the lungs
and GI tract, including eosinophilic and mononuclear in-
filtrates, increased mucus production, and epithelial cell
hyperplasia and hypertrophy. Since IL-5 is critical for the
differentiation and the release of eosinophils from the
bone marrow (Karlen et al., 1998; Roboz and Rafii,
1999), the observed blood eosinophilia in IL-33-treated
mice is likely directly related to the elevated serum level
of IL-5. The histological changes seen in the lungs and
digestive tracts in IL-33-treated animals can be ex-
pected to be linked to enhanced IL-13 protein expres-
sion as the primary mediator of these changes, since
IL-13 has been shown to be necessary for the increased
mucus production and airway hyperresponsiveness
(Corry, 1999). We confirmed this by treating IL-13 KO
mice with IL-33 for 7 days. No epithelial changes were
observed in the lungs of these IL-33-treated IL-13 KO
mice (see Figure S1 in the Supplemental Data available
with this article online).
We demonstrate that IL-33 signal transduction de-
pends on expression of ST2. The result of IL-33-induced
signal transduction is the recruitment of IRAK, IRAK4,
MyD88, and TRAF6 to ST2, ultimately leading to the acti-
vation of NF-kB and MAP kinases. This is in contrast to
studies that showed no NF-kB activation downstream
of this receptor (Brint et al., 2002; Thomassen et al.,
1999). However, in the absence of a true ligand, these
studies invariably rely on the use of chimeric receptors
composed of extracellular domains of (for example)
IL-1R1 and IL-1RAcP, combined with the intracellular
domains of ST2. Triggering of such chimeric receptors
with IL-1a/b does not always lead to productive com-
plexes capable of initiating signal transduction and
NF-kB activation. On the basis of its inability to activate
NF-kB, ST2 has been described together with SIGIRR
as the only two members of the TIR family that are inca-
pable of inducing inflammatory responses (Brint et al.,
2002; Thomassen et al., 1999). Instead, both receptors
have been identified as negative regulators of TLR-IL-1
receptor signaling (Brint et al., 2004; Wald et al., 2003).
The mechanism by which these receptors regulate
TLR-IL-1R-driven inflammatory responses appears to
be by sequestration of ‘‘downstream’’ shared adaptorproteins. Both ST2-deficient and SIGIRR-deficient mice
accordingly show enhanced inflammatory responses to
either LPS or IL-1 injections with enhanced serum levels
of inflammatory cytokines such as IL-12 and IL-6. For
ST2, the data we present here point to an alternative ex-
planation of these findings. On cells that express ST2
such as mast cells and TH2 cells, IL-33 administration
leads to the activation of a pathway that involves
NF-kB. This activation ultimately results in the produc-
tion of the TH2-associated cytokines IL-4, IL-5, and
IL-13 and their downstream biological responses. These
TH2 cytokine-dependent responses can potentially bal-
ance ongoing inflammatory TH1 responses.
Because of their profound biological functions and the
severe pathophysiological consequences of dysregu-
lated expression, all IL-1 family members are tightly reg-
ulated, either at the ligand or receptor level or both
(Dinarello, 1997, 2000; Dunne and O’Neill, 2003). The
well-known soluble form of ST2 could play an important
role in regulating the biological activity of IL-33. The im-
portance of soluble ST2 was highlighted in several re-
cent reports that described greatly increased serum
levels of this protein in a number of human diseases, in-
cluding asthma and allergic airway inflammation, acute
myocardial infarction, and sepsis (Brunner et al., 2004;
Oshikawa et al., 2001; Shimpo et al., 2004; Tajima
et al., 2003; Weinberg et al., 2003), and several studies
have demonstrated beneficial effects of soluble ST2
treatment in animal models of disease (Coyle et al.,
1999; Leung et al., 2004; Sweet et al., 2001; Xu et al.,
1998). It is, however, not yet clear how soluble ST2 func-
tions in these diseases. Identification of IL-33 as the li-
gand for ST2 will allow us to understand the potentially
competing roles of the membrane and soluble forms of
ST2. Identification of IL-33 and its receptor ST2 as an
IL-1-related cytokine-receptor system, capable of acti-
vating NF-kB and MAP kinases, and leading to the in-
duction of TH2 cytokines, opens new opportunities to in-
vestigate and ultimately understand the intricacies of
the human immune system.
Experimental Procedures
Identification of Human and Mouse IL-33
A structural superposition of available IL-1 and FGF structures (Holm
and Sander, 1998) served as the basis for a greater alignment of di-
verse IL-1 family sequences and was used to create computational
tools (position-specific scoring matrices, HMMs, and profiles) to
search sequence databases for distant IL-1- and FGF-like proteins.
The full-length sequence of dog DVS-27 (Onda et al., 1999) (acces-
sion # BAA75891) was identified by this effort from GenBank, and
its IL-1 family assignment was secured by Superfamily (Gough and
Chothia, 2002) and 3D-PSSM (Kelley et al., 2000) fold recognition
methods that matched it to IL-1/FGF b-trefoil fold templates. The or-
thologous human and mouse sequences were deduced by sequenc-
ing ESTs (AL545605 and BE915331, respectively); the corresponding
mouse gene was located with the UCSC Genome Browser (Karolchik
et al., 2003), and the predicted genomic sequence was used to iso-
late a full-length cDNA by use of PCR from a mouse lung Marathon-
Ready library. Both sequences are deposited at GenBank (acces-
sion numbers AY905581 and AY905582, respectively).
RNA Extraction and Real-Time Quantitative PCR
for Gene Expression
For TAQMAN analysis, total RNA was isolated using RNA STAT-60
(Tel-Test, Friendswood, TX). After isopropanol precipitation, total
RNA was reextracted with phenol:chloroform:isoamyl alcohol
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Total RNA (5 mg) was subjected to treatment with DNase (Roche Mo-
lecular Biochemicals). Total RNA was reverse-transcribed using Su-
perscript II (GIBCO-BRL). Primers were designed using Primer Ex-
press (PE Biosystems) or obtained commercially from Applied
Biosystems. Real-time PCR on 10 ng of cDNA was performed as de-
scribed before (Fort et al., 2001).
In Vitro Translation of IL-33 and Digestion with Caspase-1
The cDNA of full-length IL-33 was subcloned in the pSPORT6 vector
(Invitrogen) containing the SP6 promoter. In vitro translation was
performed by the TNT Coupled Reticulocyte Lysate System
(Promega) with [35S]methionine (Amersham Bioscience). In vitro
translated IL-33 was either untreated or treated with 1.5 units of cas-
pase-1 (GTS Inc.) for 1 or 2 hr at 37ºC. Untreated IL-33 was incubated
for 2 hr at 37ºC. Samples were separated by SDS-PAGE. Gels were
fixed, dried, and autoradiographed.
Recombinant Protein Production
The cDNA for human IL-33 was subcloned into the expression vector
pET3a, starting with amino acid 112 of the full-length protein.
DL21(D3) (Novagen) was transformed and expression was induced
with IPTG (Fisher Scientific) at OD600 of 0.6. 2 hr after induction, bac-
teria were harvested and the pellet was resuspended in ice-cold 50
mM Tris (pH 8.0) with 1 mM EDTA (Buffer A) in the presence of Halt-
Protease inhibitor (Pierce). Bacteria were lysed by sonication. The
lysate was centrifugated (20 min, 10,000 rpm). The supernatant
was passed over HiTrap Q column (Amersham Bioscience). The
bound protein was eluted with a NaCl gradient. IL-33-containing
peak fraction was further purified via gel filtration over a
Superdex200 HR 10/30 column (Amersham Bioscience). Peak frac-
tions of >95% pure IL-33 were quantified by SDS-PAGE and Coo-
massie blue staining with lysozyme as a standard. Endotoxin levels
(0.023 eu/mg protein) were determined (BioWhittaker Limulus Ame-
bocyte Lysate QCL-1000 pyrogen testing).
Pull-Down Assay
IL-33 was biotinylated with EZ-Link Sulfo-NHS-Biotin (Pierce). Pull-
down of 2 mg biotinylated IL-33 was performed in 500 ml RIPA-Lysis
buffer (Upstate) with 50 ml of a 50% slurry of agarose bound Avidin
D (Vector Laboratories). 5 mg of extracellular ST2 -Fc (R&D Sys-
tems) was used. After incubation overnight at 4ºC, precipitates
were washed 33 with 500 ml RIPA-Lysis buffer. Proteins were sep-
arated by SDS-PAGE, electroblotted, and visualized by Western
blot/ECL with anti-ST2 (R&D Systems). Pull-down of biotinylated
IL-33 with ST2-Fc was performed as described above, only Protein
G-Sepharose (Amersham) was used instead of Avidin D. IL-33
was visualized via a Streptavidin-HRP conjugate (Pierce) and ECL
reaction.
Flow Cytometry
Cells were collected, washed, and incubated with either anti-ST2
(MD Bioscience) or isotype control antibody (rat IgG1; BD PharMin-
gen) and subsequently stained with an R-Phycoerythrin-conjugated
anti-rat IgG antibody (Jackson ImmunoResearch). Or cells were in-
cubated with biotinylated human IL-33 and the bound IL-33 was
stained with R-Phycoerythrin-conjugated Strepdavidin (Pierce).
Cells were analyzed on a FACSCalibur flow cytometer (Becton
Dickinson).
Mice and In Vivo Treatment
C57BL/6, BALB/c mice were obtained from Jackson Laboratory and
held under pathogen-free conditions at the DNAX Animal Care Facil-
ity. Mice were given i.p. phosphate-buffered saline, 0.4 or 4 mg IL-33
protein daily up to 7 days. All animal experiments described were
approved by the institutional animal care and use committee of
DNAX and are in compliance with the guidelines of the American
Association for Accreditation of Laboratory Animal Care.
Blood and Spleen Cell Analyses
Blood was collected via cardiac puncture and transferred to either
heparin collection tubes for blood analysis or serum tubes to obtain
serum. Blood was run on a blood analyzer (Advia 120, Bayer). Mouse
spleens were made into single-cell suspension, counted by hemo-cytometer, and an aliquot was used for a cytospin. Both splenic
cytospin and blood smears were stained with Haema3 (Fisher Sci-
entific) and counted to determine the relative percentage of mono-
nuclear cells, neutrophils, and eosinophils. Absolute numbers of
each cell type were calculated for individual mice.
Histologic Analyses
Microscopic examination of mouse tissues was performed on
formalin-fixed tissue sections stained with either hematoxylin/
eosin (H&E) or periodic acid-Schiff (PAS) and alcain blue.
Phosphorylation of NF-kB, IkB-a, and MAP Kinases
WTMC mast cells (Wright et al., 2003) were lysed in RIPA lysis Buffer
(Upstate) containing Complete Mini protease inhibitor cocktail
(Roche) and 10 mM Na3VO4. Proteins were separated by SDS-
PAGE, transferred to Immobilon-P membranes (Millipore), and im-
munoblotted with antibodies to phosphorylated p65 NF-kB, p65
NF-kB, phosphorylated IkB-a, phosphorylated p44/42 MAP kinases,
p44/42 MAP kinases, phosphorylated p38 MAP kinase, and p38
MAP kinase (all antibodies from Cell Signaling Technology).
Determination of Serum Ig Isotypes and Cytokine Levels
Determination of Serum Ig was described previously (Fort et al.,
2001). Cytokine levels were determined by using Mouse Inflamma-
tion and TH1/TH2 Cytometric Bead Array Kits (BD Biosciences).
IL-13 was detected by enzyme-linked immunoabsorbent assay
(ELISA) with paired antibodies (R&D Systems). IFNg, IL-4, IL-5, and
IL-13 were detected using a Beadlyte Kit and Reagent (Upstate)
and the luminex100 detection system (Luminex).
TH1 and TH2 Polarization of Naive Mouse Cells
Naive T cells were isolated from C57BL/6 spleens by use of the
CD4+CD62L+ T Cell Isolation Kit and an AutoMACS separator (Mil-
tenyi Biotec). Polarization of naive T cell into TH1 or TH2 cells has
been described previously (Boonstra et al., 2001). After three rounds
of polarization, 43 105 cells were restimulated with plate bound anti-
CD3 and 1 mg/ml anti-CD28 with or without IL-33 (20 ng/ml). After
48 hr, supernatants were collected and monitored for cytokines.
Transient Transfection and Reporter Gene Assays
HEK293FT cells were seeded before transfection with an NF-kB-
driven GFP reporter gene construct (pNF-kB-hrGFP; Stratagene)
and with a plasmid encoding ST2 as indicated with Fugene-6
(Roche). Cells were split 24 hr after transfection. After 24 hr, cells
were either left untreated or stimulated with mouse IL-33 at the con-
centration of 50 ng/ml. 16 hr after stimulation, cells were analyzed for
GFP expression by FACS.
Immunoprecipitations
HEK293 cells were transiently transfected with human ST2 expres-
sion vector using the calcium-phosphate method. 36 hr after trans-
fection, cells untreated or treated with IL-33 (10 ng/ml) were lysed
(1.0% Nonidet P-40, 20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1.0
mM EDTA, 10 mM b-glycerophosphate, 10 mM NaF, 1 mM sodium
orthovanadate, 2 mM EGTA, 20 mM aprotinin, 1 mM phenylmethyl-
sulfonyl fluoride). Cell extracts were incubated with 1 mg of antibody
or preimmune serum for 2 hr, followed by a 2 hr incubation with 20 ml
of protein A-Sepharose beads. After incubation, the beads were
washed four times with lysis buffer, separated by SDS-PAGE, trans-
ferred to Immobilon-P membranes (Millipore), and analyzed by im-
munoblotting. Antibodies ST2 (R&D Systems), MyD88 (Stressgen),
TRAF6 (Santa Cruz Biotechnologies), IRAK (Santa Cruz Biotechnol-
ogies), and IRAK4 (Upstate) were used.
Supplemental Data
Supplemental Data include one figure and can be found with this
article online at http://www.immunity.com/cgi/content/full/23/5/
479/DC1/.
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